EP3344275 - PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 12.01.2024 Database last updated on 03.09.2024 | |
Former | The patent has been granted Status updated on 03.02.2023 | ||
Former | Grant of patent is intended Status updated on 19.09.2022 | ||
Former | Examination is in progress Status updated on 03.04.2020 | ||
Former | Request for examination was made Status updated on 08.06.2018 | ||
Former | The international publication has been made Status updated on 11.03.2017 | Most recent event Tooltip | 02.08.2024 | Lapse of the patent in a contracting state New state(s): BE | published on 04.09.2024 [2024/36] | Applicant(s) | For all designated states Aileron Therapeutics, Inc. 285 Summer Street, Unit 101 Boston, MA 02210 / US | [2023/12] |
Former [2018/28] | For all designated states Aileron Therapeutics, Inc. 281 Albany Street Cambridge, MA 02139 / US | Inventor(s) | 01 /
AIVADO, Manuel 127 Magnolia Drive Chester Springs, Pennsylvania 19425 / US | 02 /
GUERLAVAIS, Vincent 43 Kenliworth Road Arlington, Massachusetts 02476 / US | 03 /
OLSON, Karen 174 Lakeview Avenue Waltham, Massachusetts 02451 / US | [2018/28] | Representative(s) | Avidity IP Broers Building Hauser Forum 21 JJ Thomson Avenue Cambridge CB3 0FA / GB | [2018/28] | Application number, filing date | 16843105.4 | 02.09.2016 | [2018/28] | WO2016US50194 | Priority number, date | US201562214142P | 03.09.2015 Original published format: US 201562214142 P | US201662310254P | 18.03.2016 Original published format: US 201662310254 P | US201662344651P | 02.06.2016 Original published format: US 201662344651 P | US201662344791P | 02.06.2016 Original published format: US 201662344791 P | [2018/28] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017040990 | Date: | 09.03.2017 | Language: | EN | [2017/10] | Type: | A1 Application with search report | No.: | EP3344275 | Date: | 11.07.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 09.03.2017 takes the place of the publication of the European patent application. | [2018/28] | Type: | B1 Patent specification | No.: | EP3344275 | Date: | 08.03.2023 | Language: | EN | [2023/10] | Type: | B8 Corrected title page of specification | No.: | EP3344275 | Date: | 12.04.2023 | [2023/15] | Search report(s) | International search report - published on: | AU | 09.03.2017 | (Supplementary) European search report - dispatched on: | EP | 29.03.2019 | Classification | IPC: | A61K31/337, A61K31/357, A61K31/7068, A61K38/12, A61K38/15, A61K38/21, A61K38/50, A61K45/06, A61P35/00, A61K31/436, A61K31/437, A61K31/44, A61K31/475, A61K31/506, A61K31/519, A61K31/553, A61K31/565, A61K31/573, A61K31/664, A61K31/706, A61K31/555 | [2022/39] | CPC: |
A61K38/08 (EP,KR,US);
A61K38/12 (EP,KR,US);
C07K7/56 (KR,US);
A61K31/337 (EP,KR,US);
A61K31/357 (EP,US);
A61K31/436 (EP,US);
A61K31/437 (EP,US);
A61K31/44 (EP,US);
A61K31/475 (EP,US);
A61K31/506 (EP,US);
A61K31/519 (EP,US);
A61K31/553 (EP,US);
A61K31/555 (EP,US);
A61K31/565 (EP,US);
A61K31/573 (EP,US);
A61K31/664 (EP,US);
A61K31/706 (EP,US);
A61K31/7068 (EP,KR,US);
A61K33/243 (EP,US);
A61K38/15 (EP,KR,US);
A61K38/21 (EP,KR,US);
A61K38/50 (EP,KR,US);
A61K39/39558 (KR,US);
A61K45/06 (EP,KR,US);
A61P35/00 (EP,KR);
A61P35/02 (EP);
A61P43/00 (EP);
C12Y305/01001 (EP,US);
G01N33/5023 (US);
A61K2300/00 (KR);
| C-Set: |
A61K31/337, A61K2300/00 (EP,US);
A61K31/357, A61K2300/00 (EP,US);
A61K31/44, A61K2300/00 (US,EP);
A61K31/555, A61K2300/00 (EP,US);
A61K31/7068, A61K2300/00 (EP,US);
A61K33/243, A61K2300/00 (EP,US);
A61K38/12, A61K2300/00 (US,EP);
A61K38/15, A61K2300/00 (US,EP); |
Former IPC [2019/18] | A61K38/12, A61K38/15, A61K38/21, A61K38/50, A61K31/7068, A61K31/337, A61K31/357, A61K45/06, A61P35/00 | ||
Former IPC [2018/28] | A61K38/12, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/28] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | PEPTIDOMIMETISCHE MAKROZYKLEN UND VERWENDUNGEN DAVON | [2018/28] | English: | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | [2018/28] | French: | MACROCYCLES PEPTIDOMIMÉTIQUES ET LEURS UTILISATIONS | [2018/28] | Entry into regional phase | 16.03.2018 | National basic fee paid | 16.03.2018 | Search fee paid | 16.03.2018 | Designation fee(s) paid | 16.03.2018 | Examination fee paid | Examination procedure | 16.03.2018 | Examination requested [2018/28] | 16.03.2018 | Date on which the examining division has become responsible | 23.10.2019 | Amendment by applicant (claims and/or description) | 07.04.2020 | Despatch of a communication from the examining division (Time limit: M04) | 17.08.2020 | Reply to a communication from the examining division | 10.12.2020 | Despatch of a communication from the examining division (Time limit: M04) | 20.04.2021 | Reply to a communication from the examining division | 20.09.2022 | Communication of intention to grant the patent | 26.01.2023 | Fee for grant paid | 26.01.2023 | Fee for publishing/printing paid | 26.01.2023 | Receipt of the translation of the claim(s) | Opposition(s) | 11.12.2023 | No opposition filed within time limit [2024/07] | Fees paid | Renewal fee | 27.09.2018 | Renewal fee patent year 03 | 27.09.2019 | Renewal fee patent year 04 | 28.09.2020 | Renewal fee patent year 05 | 27.09.2021 | Renewal fee patent year 06 | 27.09.2022 | Renewal fee patent year 07 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AT | 08.03.2023 | CZ | 08.03.2023 | DK | 08.03.2023 | EE | 08.03.2023 | ES | 08.03.2023 | FI | 08.03.2023 | HR | 08.03.2023 | IT | 08.03.2023 | LT | 08.03.2023 | LV | 08.03.2023 | MC | 08.03.2023 | NL | 08.03.2023 | PL | 08.03.2023 | RO | 08.03.2023 | RS | 08.03.2023 | SE | 08.03.2023 | SI | 08.03.2023 | SK | 08.03.2023 | SM | 08.03.2023 | NO | 08.06.2023 | GR | 09.06.2023 | IS | 08.07.2023 | PT | 10.07.2023 | IE | 02.09.2023 | LU | 02.09.2023 | BE | 30.09.2023 | CH | 30.09.2023 | [2024/36] |
Former [2024/34] | AT | 08.03.2023 | |
CZ | 08.03.2023 | ||
DK | 08.03.2023 | ||
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
IT | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
MC | 08.03.2023 | ||
NL | 08.03.2023 | ||
PL | 08.03.2023 | ||
RO | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SI | 08.03.2023 | ||
SK | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
IS | 08.07.2023 | ||
PT | 10.07.2023 | ||
IE | 02.09.2023 | ||
LU | 02.09.2023 | ||
CH | 30.09.2023 | ||
Former [2024/33] | AT | 08.03.2023 | |
CZ | 08.03.2023 | ||
DK | 08.03.2023 | ||
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
IT | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
MC | 08.03.2023 | ||
NL | 08.03.2023 | ||
PL | 08.03.2023 | ||
RO | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SI | 08.03.2023 | ||
SK | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
IS | 08.07.2023 | ||
PT | 10.07.2023 | ||
IE | 02.09.2023 | ||
LU | 02.09.2023 | ||
Former [2024/28] | AT | 08.03.2023 | |
CZ | 08.03.2023 | ||
DK | 08.03.2023 | ||
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
IT | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
MC | 08.03.2023 | ||
NL | 08.03.2023 | ||
PL | 08.03.2023 | ||
RO | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SI | 08.03.2023 | ||
SK | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
IS | 08.07.2023 | ||
PT | 10.07.2023 | ||
LU | 02.09.2023 | ||
Former [2024/26] | AT | 08.03.2023 | |
CZ | 08.03.2023 | ||
DK | 08.03.2023 | ||
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
IT | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
PL | 08.03.2023 | ||
RO | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SI | 08.03.2023 | ||
SK | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
IS | 08.07.2023 | ||
PT | 10.07.2023 | ||
LU | 02.09.2023 | ||
Former [2024/25] | AT | 08.03.2023 | |
CZ | 08.03.2023 | ||
DK | 08.03.2023 | ||
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
PL | 08.03.2023 | ||
RO | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SI | 08.03.2023 | ||
SK | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
IS | 08.07.2023 | ||
PT | 10.07.2023 | ||
LU | 02.09.2023 | ||
Former [2024/10] | AT | 08.03.2023 | |
CZ | 08.03.2023 | ||
DK | 08.03.2023 | ||
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
PL | 08.03.2023 | ||
RO | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SI | 08.03.2023 | ||
SK | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
IS | 08.07.2023 | ||
PT | 10.07.2023 | ||
Former [2023/50] | AT | 08.03.2023 | |
CZ | 08.03.2023 | ||
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
PL | 08.03.2023 | ||
RO | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SK | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
IS | 08.07.2023 | ||
PT | 10.07.2023 | ||
Former [2023/49] | AT | 08.03.2023 | |
CZ | 08.03.2023 | ||
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
RO | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
PT | 10.07.2023 | ||
Former [2023/48] | AT | 08.03.2023 | |
EE | 08.03.2023 | ||
ES | 08.03.2023 | ||
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
PT | 10.07.2023 | ||
Former [2023/46] | ES | 08.03.2023 | |
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
SM | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
PT | 10.07.2023 | ||
Former [2023/38] | ES | 08.03.2023 | |
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
NL | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
Former [2023/37] | ES | 08.03.2023 | |
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
NO | 08.06.2023 | ||
GR | 09.06.2023 | ||
Former [2023/36] | ES | 08.03.2023 | |
FI | 08.03.2023 | ||
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
LV | 08.03.2023 | ||
RS | 08.03.2023 | ||
SE | 08.03.2023 | ||
NO | 08.06.2023 | ||
Former [2023/35] | ES | 08.03.2023 | |
HR | 08.03.2023 | ||
LT | 08.03.2023 | ||
RS | 08.03.2023 | ||
NO | 08.06.2023 | ||
Former [2023/34] | ES | 08.03.2023 | |
LT | 08.03.2023 | ||
RS | 08.03.2023 | ||
Former [2023/33] | ES | 08.03.2023 | |
LT | 08.03.2023 | Documents cited: | Search | [ ] - No further relevant documents disclosed | International search | [X]WO2012021874 (AILERON THERAPEUTICS INC [US], et al) [X] 1-56, 94-96, 214, 226 and 229-232 * abstract, pg 1 para 4 - pg 4 para 8, pg 43 para 130, claims *; | [X]WO2012021875 (AILERON THERAPEUTICS INC [US], et al) [X] 1-56, 94-96, 214, 226 and 229-232 * abstract, pg 1 para 4 - pg 4 para 8, pg 48 para 138, claims *; | [X]WO2012021876 (AILERON THERAPEUTICS INC [US], et al) [X] 1-56, 94-96, 214, 226 and 229-232 * abstract, pg 1 para 4 - pg 4 para 9, pg 32 para 105, claims *; | [X]WO2013123266 (AILERON THERAPEUTICS INC [US], et al) [X] 1-56 and 64-232 * abstract, pg 1 para 3 - pg 9 para 25, pg 50 para 158, pg 63 Table 1, claims *; | [PX]WO2016049355 (AILERON THERAPEUTICS INC [US]) [PX] 1-56 and 64-232 * abstract, pg 1 para 4 - pg 13 para 58, pg 82 Table 1, pg 159 para 319, pg 188 para 418 *; | [PX]WO2016049359 (AILERON THERAPEUTICS INC [US]) [PX] 1-56 and 64-232 * abstract, pg 1 para 3 - pg 13 para 73, pg 65 para 252, pg 90 para 336 - pg 92 para 344, pg 95 Table 3 *; | [E]WO2016154058 (AILERON THERAPEUTICS INC [US]) [E] 1-56 and 64-232* abstract, pg 2 para 4 - pg 23 para 92, pg 78 para 247, pg 109 para 325 - pg 112 para 334, pg 122 Table 3 *; | [A] - CHANG, Y. S. et al., "Stapled a-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy", Proceedings of the National Academy of Sciences, (20130000), vol. 110, no. 36, pages E3445 - E3454, XP 055333079 [A] 0 * whole document * | [A] - BROWN, C. J. et al., "Stapled peptides with improved potency and specificity that activate p53", ACS Chemical Biology., (20120000), vol. 8, no. 3, pages 506 - 512, XP 055139125 [A] 0 * whole document * | [A] - AL-LAZIKANI, B. et al., "Combinatorial drug therapy for cancer in the post- genomic era", Nature Biotechnology, (20120000), vol. 30, no. 7, pages 679 - 692, XP 055370881 [A] 0 * whole document * | [A] - LI, F. et al., "Molecular-targeted agents combination therapy for cancer: Developments and potentials", International Journal of Cancer., (20140000), vol. 134, no. 6, pages 1257 - 1269, XP055517584 [A] 0 * whole document * DOI: http://dx.doi.org/10.1002/ijc.28261 | by applicant | US4683202 | US4683195 | US5364851 | US5446128 | US5811515 | US5824483 | US6713280 | US7192713 | US7202332 | WO2008121767 | WO2008156712 | US7521051 | WO2010027827 | WO2010077634 | US2011065915 | US7932397 | WO2011066342 | US8008449 | US2011245477 | US8354509 | WO2013019906 | US8383796 | WO2013123266 | - "SwissProt", Database accession no. Q7ZUW7 | - GRUBBS et al., Acc. Chem. Res., (19950000), vol. 28, pages 446 - 452 | - YU et al., Nature, (20110000), vol. 479, page 88 | - PERYSHKOV et al., J. Am. Chem. Soc., (20110000), vol. 133, page 20754 | - VAICKUS, L., Crit Rev. in Oncol./Hemotol., (19910000), vol. 11, pages 267 - 97 | - SCHAFMEISTER et al., J. Am. Chem. Soc., (20000000), vol. 122, pages 5891 - 5892 | - SCHAFMEISTERVERDINE, J. Am. Chem. Soc., (20050000), vol. 122, page 5891 | - WALENSKY et al., Science, (20040000), vol. 305, pages 1466 - 1470 | - MUSTAPA et al., J. Org. Chem., (20030000), vol. 68, pages 8193 - 8198 | - YANG et al., Bioorg. Med. Chem. Lett., (20040000), vol. 14, pages 1403 - 1406 | - SAIKI et al., Science, (19880000), vol. 239, page 487 | - COTTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, page 4397 | - SHENK et al., Proc. Natl. Acad. Sci. USA, (19750000), vol. 72, page 989 | - CARIELLO, Human Genetics, (19880000), vol. 42, page 726 | - YANG et al., Methods Enzymol., (19860000), vol. 130, page 208 | - ANNIS, D. A.NAZEF, N.CHUANG, C. C.SCOTT, M. P.NASH, H., "A General Technique to Rank Protein-Ligand Binding Affinities and Determine Allosteric vs. Direct Binding Site Competition in Compound Mixtures", M. J. Am. Chem. Soc., (20040000), vol. 126, doi:10.1021/ja048365x, pages 15495 - 15503, XP002461719 DOI: http://dx.doi.org/10.1021/ja048365x | - "ALIS: An Affinity Selection-Mass Spectrometry System for the Discovery and Characterization of Protein-Ligand Interactions", D. A. ANNISC.-C. CHUANGN. NAZEF, Methods and Principles in Medicinal Chemistry, Wiley-VCH, vol. 2007, pages 121 - 184 | - VAICKUS, Crit Rev. Oncol./Hemotol., (19910000), vol. 11, pages 267 - 97 | - HUTCHESON et al., Breast cancer Research, (20110000), vol. 13, page R29 | - CHEN et al., Mol. Cancer Res., (20130000), vol. 11, no. 10, pages 1269 - 78 | - WHO Drug Information, (20130000), vol. 27, no. 1, pages 161 - 162 | - THOMPSON, R. H. et al., PNAS, (20040000), vol. 101, no. 49, pages 17174 - 17179 | - THOMPSON, R. H. et al., Cancer Res., (20060000), vol. 66, pages 3381 - 3385 | - GADIOT, J. et al., Cancer, (20110000), vol. 117, pages 2192 - 2201 | - TAUBE, J. M. et al., Sci Transl Med, (20120000), vol. 4, page 127ra37 | - TOPLIAN, S. L. et al., New Eng. J Med., (20120000), vol. 366, no. 26, pages 2443 - 2454 | - J. SONNEMANN et al., Invest New Drugs, (20120000), vol. 30, pages 25 - 36 | - Clin. Cancer Res., (20150000), vol. 21, no. 13, pages 2905 - 10 | - SCHAFMEISTERVERDINE, J., Am. Chem. Soc., (20050000), vol. 122, page 5891 | - "The CCP4 Suite: Programs for Protein Crystallography", Acta Crystallogr, (19940000), vol. D50, pages 760 - 763 | - P.R. EVANS, Joint CCP4 and ESF-EACBM Newsletter, (19970000), vol. 33, pages 22 - 24 | - A.VAGINA. TEPLYAKOV., J. Appl. Cryst., (19970000), vol. 30, pages 1022 - 1025 | - G.M. POPOWICZA. CZAMAU. ROTHWEILERA. SZWAGIERCZAKM. KRAJEWSKIL. WEBERT.A. HOLAK, Cell Cycle, (20070000), vol. 6, pages 2386 - 2392 | - G.N. MURSHUDOVA.A. VAGINE.J. DODSON, Acta Crystallogr, (19970000), vol. D53, pages 240 - 255 | - CHOU et al., Advances in Enzyme Regulation, (19840000), vol. 22, pages 27 - 55 | - ZHANG et al., Am J Cancer Res., (20160000), vol. 6, pages 97 - 104 |